1. Ticagrelor Fails to Unseat Clopidogrel in Elective PCI  MedPage Today
  2. ALPHEUS results do not support routine ticagrelor in elective PCI  Healio
  3. View Full coverage on Google News
More potent P2Y12 inhibitor did not curb myocardial injury, infarctionMore potent P2Y12 inhibitor did not curb myocardial injury, infarction

Ticagrelor Fails to Unseat Clopidogrel in Elective PCI | MedPage Today

Ticagrelor was not superior to clopidogrel for reducing periprocedural myocardial necrosis or myocardial injury within 48 hours of high-risk elective PCI performed in patients with stable coronary disease, according to the ALPHEUS trial.Moreover, use of ticagrelor (Brilinta, AstraZeneca) did not increase major bleeding, but did increase the rate of minor bleeding at 30 days.Ticagrelor was not superior to clopidogrel for reducing periprocedural myocardial necrosis or myocardial injury within 48 hours of high-risk elective PCI performed in patients with stable coronary disease, according to the ALPHEUS trial.Moreover, use of ticagrelor (Brilinta, AstraZeneca) did not increase major bleeding, but did increase the rate of minor bleeding at 30 days.

ALPHEUS results do not support routine ticagrelor in elective PCI